March 23, 2023
Senju Pharmaceutical has commenced a Japanese PIII study for SJP-0132, a novel compound originated by Mochida Pharmaceutical, for the treatment of dry eye disease, the partners said on March 22. The drug has been developed by Senju under a license...read more